EA
REGN icon

Emerald Acquisition’s Regeneron Pharmaceuticals REGN Stock Holding History

Emerald Acquisition’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$97.9M Sell
243,483
-6,671
-3% -$2.68M 0.19% 117
2016
Q2 		$87.3M Buy
+250,154
New +$96.3M 0.15% 156

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Emerald Acquisition's REGN Position: Q3 2016 in Review

Emerald Acquisition reduced its Regeneron Pharmaceuticals (REGN) stake by 2.7% in Q3 2016, selling an estimated $2.68M and leaving 243,483 shares worth $97.9M. The position accounts for 0.19% of the portfolio, ranked #117.

Emerald Acquisition first reported a position in REGN in Q2 2016 and has held it in 2 quarters since. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

  • Emerald Acquisition held 243,483 shares of Regeneron Pharmaceuticals worth $97.9M as of Q3 2016.
  • Emerald Acquisition sold 6,671 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $2.68M.
  • Regeneron Pharmaceuticals made up 0.19% of Emerald Acquisition's portfolio in Q3 2016, its #117 holding.
  • Emerald Acquisition first reported a position in Regeneron Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.